Urogen Pharma (URGN) Receives Average Recommendation of “Buy” from Analysts
Shares of Urogen Pharma (NASDAQ:URGN) have been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $37.67.
Several research analysts recently weighed in on the stock. UBS AG cut shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Oppenheimer Holdings, Inc. set a $51.00 price objective on shares of Urogen Pharma and gave the stock an “outperform” rating in a research report on Tuesday. Zacks Investment Research cut shares of Urogen Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, September 14th. Finally, Jefferies Group LLC boosted their price objective on shares of Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, October 9th.
Several institutional investors have recently modified their holdings of URGN. State of Tennessee Treasury Department bought a new stake in shares of Urogen Pharma during the 3rd quarter valued at $158,000. JPMorgan Chase & Co. bought a new stake in shares of Urogen Pharma during the 3rd quarter valued at $168,000. Alps Advisors Inc. bought a new stake in shares of Urogen Pharma during the 2nd quarter valued at $195,000. Shikiar Asset Management Inc. bought a new stake in shares of Urogen Pharma in the 3rd quarter valued at $665,000. Finally, LLBH Private Wealth Management LLC bought a new stake in shares of Urogen Pharma in the 2nd quarter valued at $695,000. Institutional investors own 40.55% of the company’s stock.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.